xPloration Maximizes Impact for OmniAb’s Partners through Efficient and Precise Mining of Immunized Antibody Repertoires OmniAb, Inc. &n...
Invenra Inc., a biotechnology company specializing in the discovery and development of multispecific antibodies, announced that its collaboration par...
BD a leading global medical technology company, announced the global commercial launch of the world's first cell analyzer featuring breakthrough spectral...
British techbio innovator Etcembly has signed a collaboration agreement with DJS Antibodies, a part of AbbVie, to accelerate the discovery of novel antib...
10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the first quarter ended March 31...
Worldwide first artificial Human Platelet Lysate (HPL) solution – a key ingredient for the research & production of cell-based pharmaceutical...
Qosina, a global leader in the distribution of single-use medical and biopharmaceutical components, is proud to announce a new strategic partnership with...
GeneFab, a next-generation cell and gene therapy-focused contract research, development, and manufacturing organization (CRDMO), has partnered with RegCe...
Global CDMO supports South Korean company on a multiphase project at its Copenhagen and Chiba sites AGC Biologics, your friendly CDMO expert, ...
The U.S. FDA has approved SELARSDI™ (ustekinumab-aekn) as interchangeable with the reference biologic Stelara® (ustekinumab) in all presentat...
Along with PCI’s own robust infrastructure expansions, acquisition furthers CDMO’s recent growth in sterile fill-finish, advanced drug delivery...
Biomanufacturers producing protein biologics including complex modalities, will have access to a full suite of custom cell line developme...
Purchase price of $47 per share in cash represents an enterprise value of €3.0 billion ($3.4 billion), or an equity value of approximately $...
Boehringer Ingelheim and Tessellate Bio, a precision oncology company with a focus on developing novel synthetic lethality approaches, have entered into ...
© 2025 Biopharma Boardroom. All Rights Reserved.
